Toggle Nav
Close
  • Menu
  • Setting

Elacridar

Catalog No.
A3384
BCRP inhibitor
Grouped product items
SizePriceStock Qty
10mM (in 1mL DMSO)
$77.00
In stock
10mg
$72.00
In stock
50mg
$231.00
In stock
100mg
$347.00
In stock
For scientific research use only and should not be used for diagnostic or medical purposes.

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

Background

Elacridar (CAS: 143664-11-3) is a potent inhibitor of P-glycoprotein (P-gp), a transmembrane efflux transporter belonging to the MDR/TAP subfamily. P-gp actively exports diverse xenobiotics and drugs from cells, significantly influencing drug bioavailability and distribution. Elacridar inhibits P-gp with an IC50 of approximately 193 nM and markedly reduces transporter activity in P-gp-overexpressing MDCKII cell models at concentrations as low as 1 μM. In mice, elacridar administration (10 mg/kg) enhances brain penetration of P-gp substrates such as sunitinib. Thus, elacridar is extensively used in biomedical research to study drug transport mechanisms and multidrug resistance.

Product Citation

Chemical Properties

Physical AppearanceA solid
StorageStore at -20°C
M.Wt563.64
Cas No.143664-11-3
FormulaC34H33N3O5
SynonymsGF120918;GW0918;GG918;GF-120918;GF 120918
Solubility≥56.4 mg/mL in DMSO; insoluble in EtOH; insoluble in H2O
Chemical NameN-[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]-5-methoxy-9-oxo-10H-acridine-4-carboxamide
SDFDownload SDF
Canonical SMILESCOC1=CC=CC2=C1NC3=C(C2=O)C=CC=C3C(=O)NC4=CC=C(C=C4)CCN5CCC6=CC(=C(C=C6C5)OC)OC
Shipping ConditionSmall Molecules with Blue Ice, Modified Nucleotides with Dry Ice.
General tips We do not recommend long-term storage for the solution, please use it up soon.

Protocol

Cell experiment [1]:

Cell lines

Human renal carcinoma cell lines 786-O and human breast cancer cell line MCF-7

Preparation method

The solubility of this compound in DMSO is > 56.4mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.

Reacting condition

5 μM, 24 h

Applications

Elacridar is a P-glycoprotein inhibitor that also block ABC Sub-family B Member 2 (ABCG2). Elacridar significantly enhanced sunitinib-induced cytotoxicity in 786-O cells. Confirmed by P-glycoprotein function assay, P-glycoprotein activity was inhibited by elacridar.

Animal experiment [2]:

Animal models

10-14-week wild-type, Abcb1a/1b-/-, 32Abcg2-/-27 and Abcb1a/1b/Abcg2-/- mice, all of a >99% FVB genetic background

Dosage form

Oral administration, 100 mg/kg

Application

Elacridar significantly increased sunitinib brain accumulation in wild-type mice (12-fold), to levels equal to those in Abcb1a/1b/Abcg2-/- mice. The sunitinib brain concentrations were not significantly affected by elacridar treatment in Abcb1a/1b/Abcg2-/- mice.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

[1]. Sato H, Siddig S, Uzu M, et al. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells[J]. European journal of pharmacology, 2015, 746: 258-266.

[2]. Tang S C, Lagas J S, Lankheet N A G, et al. Brain accumulation of sunitinib is restricted by P‐glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration[J]. International journal of cancer, 2012, 130(1): 223-233.

Biological Activity

Description Elacridar (GF120918; GW0918) is an inhibitor of P-glycoprotein.
Targets P-glycoprotein          
IC50            

Quality Control